179 related articles for article (PubMed ID: 22043999)
1. Hepatocarcinogenesis and ceramide/cholesterol metabolism.
Morales A; Mari M; Garcia-Ruiz C; Colell A; Fernandez-Checa JC
Anticancer Agents Med Chem; 2012 May; 12(4):364-75. PubMed ID: 22043999
[TBL] [Abstract][Full Text] [Related]
2. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
[TBL] [Abstract][Full Text] [Related]
3. Targeting Ceramide Metabolism in Hepatocellular Carcinoma: New Points for Therapeutic Intervention.
Grbčić P; Car EPM; Sedić M
Curr Med Chem; 2020; 27(39):6611-6627. PubMed ID: 31544710
[TBL] [Abstract][Full Text] [Related]
4. Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic.
Kester M; Bassler J; Fox TE; Carter CJ; Davidson JA; Parette MR
Biol Chem; 2015 Jun; 396(6-7):737-47. PubMed ID: 25838296
[TBL] [Abstract][Full Text] [Related]
5. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
Buechler C; Aslanidis C
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 May; 1865(5):158658. PubMed ID: 32058031
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial Cholesterol and the Paradox in Cell Death.
García-Ruiz C; Ribas V; Baulies A; Fernández-Checa JC
Handb Exp Pharmacol; 2017; 240():189-210. PubMed ID: 28035533
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value of Systemic Cholesteryl Ester/Free Cholesterol Ratio in Hepatocellular Carcinoma.
Krautbauer S; Weiss TS; Wiest R; Schacherer D; Liebisch G; Buechler C
Anticancer Res; 2017 Jul; 37(7):3527-3535. PubMed ID: 28668842
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.
Montero J; Morales A; Llacuna L; Lluis JM; Terrones O; Basañez G; Antonsson B; Prieto J; García-Ruiz C; Colell A; Fernández-Checa JC
Cancer Res; 2008 Jul; 68(13):5246-56. PubMed ID: 18593925
[TBL] [Abstract][Full Text] [Related]
9. Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma.
Krautbauer S; Meier EM; Rein-Fischboeck L; Pohl R; Weiss TS; Sigruener A; Aslanidis C; Liebisch G; Buechler C
Biochim Biophys Acta; 2016 Nov; 1861(11):1767-1774. PubMed ID: 27570113
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mitochondrial respiration overcomes hepatocellular carcinoma chemoresistance.
Sun Y; Xu H; Chen X; Li X; Luo B
Biochem Biophys Res Commun; 2019 Jan; 508(2):626-632. PubMed ID: 30522865
[TBL] [Abstract][Full Text] [Related]
11. The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading.
Baulies A; Montero J; Matías N; Insausti N; Terrones O; Basañez G; Vallejo C; Conde de La Rosa L; Martinez L; Robles D; Morales A; Abian J; Carrascal M; Machida K; Kumar DBU; Tsukamoto H; Kaplowitz N; Garcia-Ruiz C; Fernández-Checa JC
Redox Biol; 2018 Apr; 14():164-177. PubMed ID: 28942194
[TBL] [Abstract][Full Text] [Related]
12. Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma.
Yin X; Xiao Y; Han L; Zhang B; Wang T; Su Z; Zhang N
AAPS PharmSciTech; 2018 Jul; 19(5):2133-2143. PubMed ID: 29714002
[TBL] [Abstract][Full Text] [Related]
13. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
[TBL] [Abstract][Full Text] [Related]
14. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
Liu M; Gu P; Guo W; Fan X
Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of cholesterol, triglycerides and ceramides in hepatocellular carcinomas of diethylnitrosamine injected mice.
Haberl EM; Pohl R; Rein-Fischboeck L; Höring M; Krautbauer S; Liebisch G; Buechler C
Lipids Health Dis; 2021 Oct; 20(1):135. PubMed ID: 34629057
[TBL] [Abstract][Full Text] [Related]
16. The unfolding role of ceramide in coordinating retinoid-based cancer therapy.
Ghandour B; Dbaibo G; Darwiche N
Biochem J; 2021 Oct; 478(19):3621-3642. PubMed ID: 34648006
[TBL] [Abstract][Full Text] [Related]
17. V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy.
Bartel K; Winzi M; Ulrich M; Koeberle A; Menche D; Werz O; Müller R; Guck J; Vollmar AM; von Schwarzenberg K
Oncotarget; 2017 Feb; 8(6):9476-9487. PubMed ID: 28036299
[TBL] [Abstract][Full Text] [Related]
18. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
[TBL] [Abstract][Full Text] [Related]
19. Ceramide Metabolism Balance, a Multifaceted Factor in Critical Steps of Breast Cancer Development.
García-González V; Díaz-Villanueva JF; Galindo-Hernández O; Martínez-Navarro I; Hurtado-Ureta G; Pérez-Arias AA
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149660
[TBL] [Abstract][Full Text] [Related]
20. [Recent advances in study of sphingolipids on liver diseases].
Wang SY; Zhang JL; Zhang D; Bao XQ; Sun H
Yao Xue Xue Bao; 2015 Dec; 50(12):1551-8. PubMed ID: 27169276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
